BAT Kenya Faces Delay in New Nicotine Pouch Product Launch

BAT by 2FIRSTS.ai
May.07.2024
BAT Kenya Faces Delay in New Nicotine Pouch Product Launch
BAT Kenya's new nicotine pouch production delayed due to lack of regulatory approval, impacting $23.7 million factory operations.

According to the African media outlet BusinessDaily Africa, on May 7, the Kenyan branch of the British American Tobacco Company (BAT) is unable to meet the growing demand for its new nicotine pouch product due to a lack of approval from regulatory authorities. This has resulted in a delay in the operation of their 2.5 billion Kenyan Shilling (approximately 23.7 million US dollars) factory, which was intended to produce new products for the African market.

 

BAT Kenya noted in its annual report that despite strong performance in the local market, the supply chain was disrupted at the end of last year due to the factory still not being operational.

 

BAT Kenya stated in a report that, "We plan to expedite the reduction of tobacco hazards in 2023 and reintroduce our nicotine pouch products in the Kenyan market by 2022. However, by the end of the year, our supply of nicotine pouches in the Kenyan market was disrupted due to regulatory uncertainty. This also affected the commercialization of our modern oral nicotine products manufacturing facility."

 

In 2019, the cigarette manufacturer BAT launched its nicotine pouch brand Lifyt in the Kenyan market for the first time. However, it was banned because it was classified as a pharmaceutical product rather than a tobacco product. The ban was lifted in 2022 after the nicotine pouches were agreed to be classified as tobacco products by the Tobacco Control Committee. BAT reintroduced the product to the market in 2023 under a new brand, Velo. Despite various pressures, the new nicotine pouch manufacturing facility is yet to be implemented.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
Liverpool City Region Considers Healthier Advertising Rules for Trains, Ferries and Buses — Vapes Included
The Liverpool City Region is considering a region-wide clampdown on advertising for junk food, sugary drinks and vapes on publicly owned infrastructure. The move is framed as part of a broader push to promote healthier lifestyles and tackle deep-rooted health inequalities, with a particular focus on reducing children’s exposure to harmful marketing in public spaces. The plan is set to go before the Combined Authority on Friday.
Jan.23 by 2FIRSTS.ai
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s Tobacco and Vape Retail Licensing Regime Takes Effect; BAT Says It Should Cover Nicotine Pouches
Ireland’s retail licensing system took effect on Feb. 2, 2026, charging annual fees per point of sale and enforced by the Health Service Executive (HSE). British American Tobacco’s local unit, BAT Ireland, said excluding nicotine pouches could leave a regulatory gap.
Feb.04 by 2FIRSTS.ai
Product | UWELL Launches CALIBURN BAR 80K Disposable Vape, Rated for 80,000 Puffs with 6 Power Levels and 3 Airflow Settings
Product | UWELL Launches CALIBURN BAR 80K Disposable Vape, Rated for 80,000 Puffs with 6 Power Levels and 3 Airflow Settings
UWELL has launched the CALIBURN BAR 80K disposable vape on its official website. The device features a staggering 80,000-puff count and a 20 mg/ml nicotine concentration. It offers two output modes (NORMAL and BOOST) with six adjustable power levels ranging from 18W to 35W, complemented by a 3-level airflow adjustment system.
Jan.14 by 2FIRSTS.ai
Make Your Brand Understood by the People Who Matter
Make Your Brand Understood by the People Who Matter
Feb.02
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G said its HNB brand lil has grown since launch, reporting KRW 7.8 billion (about US$5.304 million) in sales in 2017 and about KRW 4.3 trillion (about US$2.924 billion) in cumulative sales by last year’s third quarter, with KRW 5 trillion (about US$3.400 billion) described as within reach. KT&G said lil has entered more than 30 countries and supplies some products abroad via a partnership with PMI.
Jan.13 by 2FIRSTS.ai